Integra LifeSciences Holdings Corporation (NASDAQ: IART) and Ocular Therapeutix (NASDAQ:OCUL) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, institutional ownership, profitability, dividends and earnings.

Earnings & Valuation

This table compares Integra LifeSciences Holdings Corporation and Ocular Therapeutix’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Integra LifeSciences Holdings Corporation $1.05 billion 3.79 $240.98 million $0.82 62.12
Ocular Therapeutix $1.90 million 88.39 -$54.64 million ($2.13) -2.71

Integra LifeSciences Holdings Corporation has higher revenue and earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Integra LifeSciences Holdings Corporation, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Integra LifeSciences Holdings Corporation and Ocular Therapeutix, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Integra LifeSciences Holdings Corporation 0 2 7 0 2.78
Ocular Therapeutix 0 2 5 0 2.71

Integra LifeSciences Holdings Corporation presently has a consensus price target of $53.56, suggesting a potential upside of 5.13%. Ocular Therapeutix has a consensus price target of $22.29, suggesting a potential upside of 285.57%. Given Ocular Therapeutix’s higher possible upside, analysts plainly believe Ocular Therapeutix is more favorable than Integra LifeSciences Holdings Corporation.

Profitability

This table compares Integra LifeSciences Holdings Corporation and Ocular Therapeutix’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Integra LifeSciences Holdings Corporation 6.27% 16.79% 7.35%
Ocular Therapeutix -3,005.52% -101.03% -69.76%

Institutional and Insider Ownership

84.9% of Integra LifeSciences Holdings Corporation shares are held by institutional investors. Comparatively, 53.3% of Ocular Therapeutix shares are held by institutional investors. 21.5% of Integra LifeSciences Holdings Corporation shares are held by insiders. Comparatively, 26.1% of Ocular Therapeutix shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Volatility and Risk

Integra LifeSciences Holdings Corporation has a beta of 0.71, meaning that its stock price is 29% less volatile than the S&P 500. Comparatively, Ocular Therapeutix has a beta of 1.58, meaning that its stock price is 58% more volatile than the S&P 500.

Summary

Integra LifeSciences Holdings Corporation beats Ocular Therapeutix on 9 of the 13 factors compared between the two stocks.

About Integra LifeSciences Holdings Corporation

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions. It sells products and solutions for dural repair, precision tools and instruments, tissue ablation and neuro critical care. It also sells regenerative technology products for treating acute wounds, such as burns, and chronic wounds, including diabetic foot ulcers and surgical tissue repair. Its products are used in neurosurgery, extremity reconstruction, orthopedics and general surgery.

About Ocular Therapeutix

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its lead product candidate, DEXTENZA (dexamethasone insert) for intracanalicular use, has completed Phase III clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. OTX-TP (travoprost insert) is in Phase III clinical development for glaucoma and ocular hypertension. Its earlier stage assets include OTX-TIC, a sustained release travoprost intracameral injection for the treatment of moderate to severe glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. These injections include the development of OTX-TKI, a tyrosine kinase inhibitor, and, in collaboration with Regeneron an extended release protein-based anti-vascular endothelial growth factor trap.

Receive News & Ratings for Integra LifeSciences Holdings Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences Holdings Corporation and related companies with MarketBeat.com's FREE daily email newsletter.